GRAIL, Inc. (GRAL)

GRAIL, Inc. is a biotechnology company specializing in early cancer detection. Their flagship product, Galleri, is a screening test for asymptomatic individuals over 50.

47/100 AI Score MCap 3B Vol 569K

Company Overview

CEORobert Ragusa
Employees1000
HeadquartersMenlo Park, CA, US
IPO Year2024

GRAIL, Inc. pioneers early cancer detection with Galleri, a groundbreaking screening test targeting asymptomatic individuals, positioning them to revolutionize diagnostics and capture a significant share of the multi-billion dollar cancer screening market, despite current unprofitability.

Investment Thesis

Investing in GRAIL, Inc. presents a high-risk, high-reward opportunity centered on its Galleri multi-cancer early detection test. While the company currently operates with a negative profit margin of -286.4% and a negative gross margin of -47.5%, the potential market for early cancer detection is substantial. The key value driver is the widespread adoption of Galleri, which could significantly improve cancer survival rates and reduce healthcare costs. Upcoming catalysts include expanded clinical validation of Galleri, securing reimbursement agreements with major payers, and successful marketing campaigns to drive consumer demand. The investment thesis hinges on GRAIL's ability to demonstrate the clinical utility and cost-effectiveness of Galleri, ultimately establishing it as a standard of care for cancer screening. However, the high beta of 4.55 reflects the significant volatility and uncertainty associated with this investment.

Key Highlights

  • Market Cap of $3.90B reflects investor interest in the potential of early cancer detection.
  • P/E ratio of -8.90 indicates that the company is currently unprofitable, common for growth-stage biotechnology companies.
  • Negative Profit Margin of -286.4% highlights the significant investments in research, development, and commercialization.
  • Beta of 4.55 suggests high volatility compared to the overall market, reflecting the speculative nature of the stock.
  • Galleri, a multi-cancer early detection blood test, represents a potential breakthrough in cancer screening.

Competitors

Strengths

  • Innovative multi-cancer early detection technology (Galleri).
  • Strong focus on research and development.
  • Experienced management team.
  • Potential to disrupt the cancer diagnostics market.

Weaknesses

  • Currently unprofitable with high operating expenses.
  • Reliance on successful commercialization of Galleri.
  • Regulatory and reimbursement uncertainties.
  • High beta indicates significant stock volatility.

Catalysts

  • Upcoming: Publication of additional clinical data supporting the performance of Galleri.
  • Upcoming: Securing reimbursement agreements with major payers.
  • Ongoing: Expansion of marketing and sales efforts to drive adoption of Galleri.
  • Ongoing: Development of new diagnostic tests and applications.
  • Ongoing: Strategic partnerships and collaborations.

Risks

  • Potential: Failure to obtain regulatory approvals for Galleri.
  • Potential: Inability to secure reimbursement agreements with payers.
  • Ongoing: Competition from other diagnostic companies.
  • Ongoing: High operating expenses and continued losses.
  • Potential: Negative publicity or safety concerns related to Galleri.

Growth Opportunities

  • Expansion of Galleri's Clinical Utility: GRAIL can expand the clinical utility of Galleri by conducting additional studies to demonstrate its effectiveness in detecting specific types of cancer and in guiding treatment decisions. This includes studies focused on high-risk populations and on cancers with limited screening options. The market size for targeted cancer screening is estimated to be substantial, with the potential to significantly improve patient outcomes and reduce healthcare costs. Timeline: Ongoing, with continuous data collection and analysis.
  • Securing Reimbursement Agreements: A critical growth opportunity lies in securing reimbursement agreements with major payers, including government healthcare programs and private insurance companies. Widespread reimbursement coverage is essential for driving adoption of Galleri and ensuring access for a broad population. The market size for reimbursed cancer screening tests is significant, representing a substantial revenue opportunity for GRAIL. Timeline: Upcoming, with ongoing negotiations with payers.
  • Strategic Partnerships: GRAIL can pursue strategic partnerships with pharmaceutical companies, healthcare providers, and other organizations to expand its reach and accelerate the adoption of Galleri. These partnerships could involve co-marketing agreements, joint research projects, or integration of Galleri into existing healthcare workflows. The market size for integrated diagnostic solutions is growing rapidly, driven by the increasing demand for personalized medicine. Timeline: Ongoing, with continuous exploration of partnership opportunities.
  • International Expansion: Expanding into international markets represents a significant growth opportunity for GRAIL. Many countries lack comprehensive cancer screening programs, creating a substantial unmet need for early detection technologies. The market size for cancer screening in international markets is estimated to be substantial, with the potential to generate significant revenue for GRAIL. Timeline: Upcoming, with initial focus on select European and Asian markets.
  • Development of Post-Diagnostic Tests: GRAIL is developing minimal residual disease (MRD) and other post-diagnostic tests to monitor cancer recurrence and treatment response. These tests have the potential to improve patient outcomes by enabling earlier detection of recurrence and more personalized treatment strategies. The market size for post-diagnostic cancer testing is growing rapidly, driven by the increasing demand for precision medicine. Timeline: Ongoing, with continuous research and development efforts.

Opportunities

  • Expansion of Galleri's clinical utility through additional studies.
  • Securing reimbursement agreements with major payers.
  • Strategic partnerships with pharmaceutical companies and healthcare providers.
  • International expansion into underserved markets.

Threats

  • Competition from established diagnostic companies and emerging biotechnology firms.
  • Unfavorable regulatory changes or delays in approvals.
  • Failure to demonstrate clinical validity and cost-effectiveness of Galleri.
  • Negative publicity or safety concerns related to Galleri.

Competitive Advantages

  • Proprietary Technology: GRAIL's Galleri test is based on proprietary technology and algorithms.
  • Extensive Clinical Data: The company has generated a substantial amount of clinical data supporting the performance of Galleri.
  • First-Mover Advantage: GRAIL is among the first companies to commercialize a multi-cancer early detection blood test.
  • Strong Intellectual Property: GRAIL has a strong intellectual property portfolio protecting its technology and products.

About

GRAIL, Inc., founded in 2015 and based in Menlo Park, California, is a biotechnology company dedicated to transforming cancer detection and diagnosis. Spun out from Illumina, Inc., GRAIL is focused on developing innovative technologies that enable earlier and more accurate identification of cancer, when treatment is more likely to be successful. The company's primary product is Galleri, a multi-cancer early detection (MCED) blood test designed for asymptomatic individuals aged 50 and older. Galleri screens for a common cancer signal across more than 50 types of cancer, many of which lack recommended screening tests today. In addition to Galleri, GRAIL is developing Diagnostic Aid for Cancer (DAC) tests to accelerate diagnostic resolution for patients with a clinical suspicion of cancer. These tests aim to provide clinicians with valuable information to guide treatment decisions and improve patient outcomes. Furthermore, GRAIL is actively developing minimal residual disease (MRD) and other post-diagnostic tests to monitor cancer recurrence and treatment response. GRAIL's commitment to innovation and its focus on early cancer detection position it as a key player in the evolving landscape of cancer diagnostics.

What They Do

  • Develops Galleri, a multi-cancer early detection blood test.
  • Screens asymptomatic individuals over 50 for a common cancer signal.
  • Aims to detect more than 50 types of cancer, many without recommended screening.
  • Develops Diagnostic Aid for Cancer (DAC) tests to accelerate cancer diagnosis.
  • Creates tests to provide clinicians with information to guide treatment decisions.
  • Develops minimal residual disease (MRD) tests to monitor cancer recurrence.
  • Focuses on early cancer detection technologies to improve patient outcomes.

Business Model

  • Generates revenue through sales of Galleri multi-cancer early detection tests.
  • Partners with healthcare providers to offer Galleri to patients.
  • Seeks reimbursement from insurance companies and government healthcare programs.
  • Develops and commercializes additional diagnostic tests for cancer.

Industry Context

GRAIL operates within the rapidly evolving medical diagnostics and research industry, specifically targeting the multi-cancer early detection market. The industry is characterized by intense competition, rapid technological advancements, and increasing demand for personalized medicine. The market for cancer diagnostics is projected to reach billions of dollars in the coming years, driven by an aging population, rising cancer incidence rates, and growing awareness of the benefits of early detection. GRAIL's competitive landscape includes established diagnostic companies and emerging biotechnology firms, all vying for a share of this lucrative market. Success hinges on demonstrating clinical validity, securing regulatory approvals, and achieving widespread adoption by healthcare providers and patients.

Key Customers

  • Asymptomatic individuals aged 50 and older seeking early cancer detection.
  • Healthcare providers who recommend and order Galleri for their patients.
  • Insurance companies and government healthcare programs that reimburse for Galleri.
  • Patients with a clinical suspicion of cancer who may benefit from DAC tests.
AI Confidence: 71% Updated: 2/8/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q4 2025 $44M -$99M $-2.44
Q3 2025 $36M -$89M $-2.46
Q2 2025 $36M -$114M $-3.25
Q1 2025 $32M -$106M $-3.10

Source: Company filings

Chart & Info

Price Chart

GRAIL, Inc. (GRAL) stock price: $95.75 (+6.88, +7.74%)

Why Bull

  • •Recent insider buying suggests confidence in GRAIL's future, indicating that leadership believes in the company's potential.
  • •Community sentiment has shifted positively, with increasing discussions around GRAIL's innovative cancer detection technologies.
  • •Partnerships with major healthcare providers are enhancing GRAIL's visibility and credibility in the market.
  • •Recent positive news coverage has highlighted GRAIL's advancements, contributing to a more favorable public perception.

Why Bear

  • •Concerns remain about the competitive landscape, with several companies developing similar cancer detection solutions.
  • •Community skepticism exists regarding the scalability of GRAIL's technology and its adoption in clinical settings.
  • •Recent earnings calls revealed challenges in meeting projected timelines, leading to doubts among investors.
  • •Market volatility and economic uncertainty could impact funding and operational capabilities for GRAIL moving forward.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
568,310

Rationale

AI-generated technical analysis for GRAL including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss GRAIL, Inc. (GRAL) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for GRAL.

Make a Prediction

Set your price target for GRAIL, Inc. (GRAL), choose a timeframe, and track your prediction accuracy.

Current price: $95.75

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRAL.

Price Targets

Wall Street price target analysis for GRAL.

Insider Flow (30d)

CHASE WILLIAM J
Insider
1 month ago
BOUGHT
36,803 shares
$3.6M
MIZELL STEVEN
Insider
1 month ago
BOUGHT
36,675 shares
$3.6M
SUMME GREGORY L
Insider
1 month ago
BOUGHT
39,123 shares
$3.8M
Ofman Joshua J.
Insider
2 months ago
SOLD
368,818 shares
$36.9M
Freidin Aaron
Insider
2 months ago
SOLD
259,077 shares
$25.7M
RAGUSA ROBERT P
Insider
2 months ago
SOLD
2,788,750 shares
$267.1M

MoonshotScore

46.5/100

Score Factors

  • Revenue Growth 4/100

    Revenue grew only 17.2% YoY, suggesting the company is in a slower growth phase.

  • Gross Margin 8/100

    Gross margin at 48.5% indicates good unit economics and healthy profitability per sale.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates GRAL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does GRAIL, Inc. do?

GRAIL, Inc. is a biotechnology company focused on early cancer detection. Its primary product, Galleri, is a multi-cancer early detection blood test designed for asymptomatic individuals aged 50 and older. Galleri screens for a common cancer signal across more than 50 types of cancer, many of which lack recommended screening tests today. GRAIL aims to transform cancer detection and diagnosis by enabling earlier and more accurate identification of cancer, when treatment is more likely to be successful. In addition to Galleri, GRAIL is developing other diagnostic tests to improve cancer care.

Is GRAL stock a good buy?

GRAL stock presents a speculative investment opportunity with significant potential upside and substantial risks. The company's Galleri test has the potential to revolutionize cancer screening, but its commercial success is not guaranteed. The negative profit margin and high beta reflect the company's current unprofitability and stock volatility. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in GRAL. Key factors to consider include the company's ability to secure reimbursement agreements, demonstrate clinical validity, and effectively compete in the cancer diagnostics market.

What are the main risks for GRAL?

The main risks for GRAL include regulatory hurdles, reimbursement challenges, and competition from other diagnostic companies. The company's Galleri test must obtain regulatory approvals from the FDA and other agencies before it can be widely marketed. Securing reimbursement agreements with payers is also critical for driving adoption of Galleri. GRAL faces competition from established diagnostic companies and emerging biotechnology firms, all vying for a share of the cancer diagnostics market. Additionally, the company's high operating expenses and continued losses pose a financial risk.

Is GRAL a good stock to buy?

Whether GRAL is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the GRAL MoonshotScore?

The MoonshotScore for GRAL is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is GRAL data updated?

GRAL stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to GRAL is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for GRAL?

Growth catalysts for GRAIL, Inc. (GRAL) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes GRAIL, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are GRAL's main competitors?

GRAIL, Inc. (GRAL) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether GRAL has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about GRAL?

Wall Street analyst coverage for GRAL includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is GRAL's market cap?

Market capitalization (market cap) for GRAL is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows GRAL's current market cap alongside enterprise value and other valuation metrics.

How has GRAL stock performed recently?

GRAL's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing GRAL's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in GRAL?

Key risk categories for GRAL include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures GRAL's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling GRAL?

Insider trading activity for GRAL tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is GRAL a good stock for beginners?

GRAIL, Inc. (GRAL) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is GRAL for first-time investors?

Every stock carries risk, including GRAIL, Inc. (GRAL). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like GRAL.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on available data and may be subject to change.
  • Investment in biotechnology companies is inherently risky.
Data Sources
profilefundamentalsexistingCopy